Aloxiprin

Oral
Pain and inflammation associated with musculoskeletal and joint disorders

Children <16 yr due to risk of Reye's syndrome, active peptic ulceration, haemophilia and other haemorrhagic disorders; hypersensitivity to aspirin or other NSAIDs. Pregnancy and lactation. Severe hepatic and renal dysfunction.

Patients with infections, dyspepsia or known to have gastric mucosal lesions. Asthma or allergic disorders. Diabetes mellitus. Impaired renal or hepatic function. Dehydration. Uncontrolled hypertension. Precipitation of acute haemolytic anaemia in G6PD patients with high doses. Avoid prolonged use in elderly. Discontinue several days prior to scheduled surgery.

GI disturbances; hypoprothrombinaemia, blood disorders eg, thrombocytopaenia; salicylism.
Potentially Fatal: Hepatotoxicity and hypersensitivity.

Earlier salicylate absorption and higher plasma concentrations with metoclopramide in migraine patients. Increased peak concentrations by metoprolol. Decreased peak concentrations and increased risk of GI bleeding and ulceration by corticosteroids. Antacids and absorbents increase excretion. Enhance activities of coumarin anticoagulants, sulfonylureas, zafirlukast, methotrexate, phenytoin and valproate. Concomitant use with other NSAIDs increases risk of side effects. Alcohol enhance GI effects.

Thyroid function tests.

Description:
Mechanism of Action: Aloxiprin is a polymeric condensation product of aluminium oxide and aspirin and has actions similar to aspirin through inhibition of COX, which in turn inhibits the biosynthesis of prostaglandins and thromboxanes. It also inhibits platelet aggregation.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)